Longeveron MSC Therapy Reverses Age-Related Frailty in Clinical Trials
【Abstract】: (Clinical Milestone) Longeveron (NASDAQ: LGVN) recently published groundbreaking Phase 2b clinical trial results in the prestigious journal Cell Stem Cell. The study demonstrates that intravenous laromestrocel—an allogeneic mesenchymal stem cell (MSC) therapy—significantly improves the physical condition and mobility of patients suffering from age-related frailty after nine months compared to a placebo.
Business Insight: This officially validates off-the-shelf MSCs as a scalable, evidence-based treatment for systemic aging. Longevity clinics and medical tourism facilitators exhibiting at CMTF can leverage this FDA-track cellular therapeutic to attract Ultra-High-Net-Worth (UHNW) patients, shifting the anti-aging market away from unproven supplements toward rigorous, high-margin regenerative medicine.
【Keywords】: #CellTherapy #LongevityBiotech #RegenerativeMedicine
【Source Link】: USA News Group / Investing News (March 2026)
